Table of Contents
ISRN Endocrinology
Volume 2013 (2013), Article ID 341632, 8 pages
http://dx.doi.org/10.1155/2013/341632
Clinical Study

Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood

1Clinical Research Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, The Ottawa Hospital, Riverside Campus, University of Ottawa, 1967 Riverside Drive, Ottawa, ON, Canada K1H 7W9
2Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada K1H 8M5
3Division of Maternal Fetal Medicine, Departments of Obstetrics and Gynaecology and Cellular Molecular Medicine, University of Ottawa, 501 Smyth Road, Box 804, Ottawa, ON, Canada K1H 8L6
4Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6
5Department of Obstetrics and Gynaecology, Winchester District Memorial Hospital, 566 Louise Street, Winchester, ON, Canada K0C 2K0

Received 9 April 2013; Accepted 15 May 2013

Academic Editors: R. Aikin, W. B. Chan, Y. Combarnous, T. Dinh, and S. Mishra

Copyright © 2013 Patricia Peticca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Mazurkiewicz, G. F. Watts, F. G. Warburton, B. M. Slavin, C. Lowy, and E. Koukkou, “Serum lipids, lipoproteins and apolipoproteins in pregnant non-diabetic patients,” Journal of Clinical Pathology, vol. 47, no. 8, pp. 728–731, 1994. View at Google Scholar · View at Scopus
  2. W. Piechota and A. Staszewski, “Reference ranges of lipids and apolipoproteins in pregnancy,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 45, no. 1, pp. 27–35, 1992. View at Google Scholar · View at Scopus
  3. N. Bansal, J. K. Cruickshank, P. McElduff, and P. N. Durrington, “Cord blood lipoproteins and prenatal influences,” Current Opinion in Lipidology, vol. 16, no. 4, pp. 400–408, 2005. View at Google Scholar · View at Scopus
  4. N. G. Seidah, S. Benjannet, L. Wickham et al., “The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 928–933, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Abifadel, M. Varret, J. Rabès et al., “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia,” Nature Genetics, vol. 34, no. 2, pp. 154–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. M. Timms, S. Wagner, M. E. Samuels et al., “A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree,” Human Genetics, vol. 114, no. 4, pp. 349–353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Cohen, A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, and H. H. Hobbs, “Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9,” Nature Genetics, vol. 37, no. 2, pp. 161–165, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Mayne, T. Dewpura, A. Raymond et al., “Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture,” Clinical Chemistry, vol. 57, no. 10, pp. 1415–1423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mayne, A. Raymond, A. Chaplin et al., “Plasma PCSK9 levels correlate with cholesterol in men but not in women,” Biochemical and Biophysical Research Communications, vol. 361, no. 2, pp. 451–456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. W. E. Alborn, G. Cao, H. E. Careskey et al., “Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol,” Clinical Chemistry, vol. 53, no. 10, pp. 1814–1819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. G. Lakoski, T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Genetic and metabolic determinants of plasma PCSK9 levels,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2537–2543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Baass, G. Dubuc, M. Tremblay et al., “Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents,” Clinical Chemistry, vol. 55, no. 9, pp. 1637–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. K. N. Maxwell and J. L. Breslow, “Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 18, pp. 7100–7105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. N. Maxwell, E. A. Fisher, and J. L. Breslow, “Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 6, pp. 2069–2074, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. A. Lagace, D. E. Curtis, R. Garuti et al., “Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 2995–3005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Zhang, T. A. Lagace, R. Garuti et al., “Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 18602–18612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Persson, G. Cao, L. Ståhle et al., “Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2666–2672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Costet, B. Cariou, G. Lambert et al., “Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c,” Journal of Biological Chemistry, vol. 281, no. 10, pp. 6211–6218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. D. Browning and J. D. Horton, “Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans,” Journal of Lipid Research, vol. 51, no. 11, pp. 3359–3363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. E. Careskey, R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad, “Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9,” Journal of Lipid Research, vol. 49, no. 2, pp. 394–398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Davignon and G. Dubuc, “Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels,” Transactions of the American Clinical and Climatological Association, vol. 120, pp. 163–173, 2009. View at Google Scholar · View at Scopus
  22. J. Mayne, T. Dewpura, A. Raymond et al., “Plasma PCSK9 levels are significantly modified by statins and fibrates in humans,” Lipids in Health and Disease, vol. 11, no. 7, p. 22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Verges, L. Duvillard, M. C. Brindisi et al., “Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes,” Atherosclerosis, vol. 219, no. 1, pp. 342–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Dube, M. Ethier-Chiasson, and J. Lafond, “Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta,” Biology of Reproduction, vol. 88, no. 1, p. 16, 2013. View at Publisher · View at Google Scholar
  25. G. Dubuc, M. Tremblay, G. Paré et al., “A new method for measurement of total plasma PCSK9: clinical applications,” Journal of Lipid Research, vol. 51, no. 1, pp. 140–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nakai, T. Tamai, and S. Yamada, “Plasma lipids and lipoproteins of Japanese adults and umbilical cord blood,” Artery, vol. 9, no. 2, pp. 132–150, 1981. View at Google Scholar · View at Scopus
  27. C. Catarino, I. Rebelo, L. Belo et al., “Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies,” Thrombosis Research, vol. 123, no. 2, pp. 219–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. V. A. Rodie, M. J. Caslake, F. Stewart et al., “Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction,” Atherosclerosis, vol. 176, no. 1, pp. 181–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Benjannet, D. Rhainds, R. Essalmani et al., “NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol,” Journal of Biological Chemistry, vol. 279, no. 47, pp. 48865–48875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Gedeon, J. Behravan, G. Koren, and M. Piquette-Miller, “Transport of glyburide by placental ABC transporters: implications in fetal drug exposure,” Placenta, vol. 27, no. 11-12, pp. 1096–1102, 2006. View at Publisher · View at Google Scholar · View at Scopus